Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001636282-25-000039
Filing Date
2025-04-14
Accepted
2025-04-14 16:40:55
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A a2025spyredefa14amaterials.htm DEFA14A 14080
2 GRAPHIC proxycardimage1.jpg GRAPHIC 142430
3 GRAPHIC proxycardimage2.jpg GRAPHIC 100422
  Complete submission text file 0001636282-25-000039.txt   349970
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37722 | Film No.: 25836470
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)